Position in OCGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$6,829,249
+$6,640,860 QoQ
Shares Held
3,773,066
+1842.7% QoQ
Ownership
1.11%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2022
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in OCGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Qube Research & Technologies Ltd holds $1,746,537,711 across 187 Biotechnology names. OCGN ranks #59 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
838,187 | $277,330,932 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
3,450,904 | $95,590,040 | |
| 3 | RPRX |
Royalty Pharma plc
|
1,524,511 | $73,130,792 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
83,358 | $64,405,725 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
335,334 | $56,678,152 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
553,290 | $53,807,452 | |
| 7 | CYTK |
Cytokinetics Inc
|
779,446 | $51,373,285 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
262,553 | $49,635,644 |
All Filings in OCGN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,829,249 | 3,773,066 | Shares | Sole | 2026-05-15 | |
| 2025-06-30 | $188,389 | 194,216 | Shares | Sole | 2025-08-14 | |
| 2023-12-31 | $1,467 | 2,552 | Shares | Sole | 2024-02-13 | |
| 2023-09-30 | $10,470 | 26,177 | Shares | Sole | 2023-11-13 | |
| 2023-06-30 | $179,223 | 330,062 | Shares | Sole | 2023-08-14 | |
| 2022-12-31 | $67,445 | 51,881 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $330,084 | 185,441 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $1,128,042 | 496,935 | Shares | Sole | 2022-08-15 | |
| No filing history on record for this holder in this stock. | ||||||